 |
|
|
| |
Perceived Barriers Related to the Management of HCVInfection Among Physicians Prescribing Opioid Agonist Therapy:The C-SCOPE Study
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
Alain H Litwin1; Martine Drolet2; Chizoba Nwankwo3; Marta Torrens4; Andrej Kastelic5; Stephan Walcher6; Lorenzo Somaini7; Emily Mulvihill8; Jochen Ertl8; Jason Grebely9
1Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY, USA; 2Merck Canada Inc., Montreal, Canada; 3Merck & Co., Inc., Kenilworth, NJ, USA; 4Institute of Neuropsychiatry and Addictions, IMIM (Hospital del Mar Medical Research Institute) and Department of Psychiatry, Universitat Autònoma de Barcelona, Barcelona, Spain; 5National Centre for Treatment of Drug Addiction, University Psychiatric Clinic Ljubljana, Slovenia, EU; 6CONCEPT, Center for Addiction-Medicine, Munich, Germany; 7Addiction Treatment Centre Local Health Unit ASL Biella, Biella, Italy; 8Kantar Health, St. Louis, MO, USA; 9The Kirby Institute, UNSW Sydney, Sydney, Australia
|
| |
|
|
|
|
|
